Certara Inc.

CERT | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.49

+$0.07 (+0.83%)

Sep 21, 2026, 2:01 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.83%

(1D)

Rating

Updated: Aug 28, 2026

30.6

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.32B

1D Range

8.43 8.55

52W Range

4.45 13.88

Valuation (TTM)

PE -19.14

PB 1.36

EV/EBITDA 17.02

Valuation (NTM)

Forward PE 21.60

Forward PEG -1.33

Price Target $7.75

Cash Flow

FCF Yield 4.7%

SBC Adj. FCF Yield 2.3%

SBC Impact -50.6%

Margins

Gross Margin 58.3%

Operating Margin 1.9%

FCF Margin 15.1%

Growth (CAGR)

Revenue 3Y | 5Y 5.1% | 9.3%

Dil EPS 3Y | 5Y 10.1% | -49.3%

FCF 3Y | 5Y -6.0% | 8.8%

Returns

ROA -4.9%

ROE -6.7%

ROIC 0.6%

Financial Health

Net Debt

$107.7M

Current Ratio 2.55

Interest Coverage 0.19

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and precl...

Sector Healthcare

Industry Medical - Healthcare Information Services

Employees 1,546

IPO Date Dec 10, 2020

Website www.certara.com

Fiscal Year January - December

Full Company Profile

Latest News

2 months ago · seekingalpha.com

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Certara Q2 Earnings Call Highlights

Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.

2 months ago · zacks.com

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

2 months ago · globenewswire.com

Certara Reports Second Quarter 2026 Financial Results

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.

2 months ago · prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

2 months ago · globenewswire.com

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

3 months ago · benzinga.com

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives with Certara Inc. (NASDAQ:CERT) and Silo Pharma Inc. (NASDAQ:SILO).

3 months ago · globenewswire.com

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.